Rucaparib Camsylate Patent Expiration

Rucaparib Camsylate is Used for treating cancers associated with deleterious BRCA mutations, such as epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer. It was first introduced by Zr Pharma And Gmbh in its drug Rubraca on Dec 19, 2016.


Rucaparib Camsylate Patents

Given below is the list of patents protecting Rucaparib Camsylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rubraca US10130636 High dosage strength tablets of rucaparib Aug 17, 2035 Zr Pharma
Rubraca US10278974 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Zr Pharma
Rubraca US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases Nov 22, 2023

(Expired)

Zr Pharma
Rubraca US7351701 Therapeutic compounds Jul 23, 2024 Zr Pharma
Rubraca US7531530 Therapeutic compounds Jul 23, 2024 Zr Pharma
Rubraca US8071579 DNA damage repair inhibitors for the treatment of cancer Aug 12, 2027 Zr Pharma
Rubraca US8143241 DNA damage repair inhibitors for treatment of cancer Aug 12, 2027 Zr Pharma
Rubraca US8754072 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Zr Pharma
Rubraca US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug 04, 2031 Zr Pharma
Rubraca US9045487 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Zr Pharma
Rubraca US9861638 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one Feb 10, 2031 Zr Pharma
Rubraca US9987285 High dosage strength tablets of rucaparib Aug 17, 2035 Zr Pharma


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳